InSphero's CEO Jan Lichtenberg wins Entrepreneur of the Year™ 2015
Schlieren, Switzerland, Oct 23, 2015 – Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG received the Ernst & Young Entrepreneur of the Year™ 2015 award in the category “Emerging Entrepreneur”. PDF Version
Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG has been awarded the Swiss EY Entrepreneur of the Year™ 2015 award for his leadership in building the Schlieren-based 3D cell culture company into a world-leading technology provider that is helping to revolutionize drug development and chemical safety testing.
Winners in four categories: Service/Trade, Industry/High-Tech/Life Sciences, Emerging Entrepreneur and Family Business were selected from 15 finalists by an independent jury, and announced this past Saturday. The four winners stood apart for their company achievement, leadership strength and convincing promotion of their company through professional and social engagement.
Since 1998 EY has tracked successful entrepreneurs in all sectors, branches, regions and markets within Switzerland. They're all courageous, innovative, willing to take risks, reliable, engaging and strong; they are the backbone of the Swiss national economy. EY Entrepreneur of the Year™ is the only entrepreneurial award program with a global dimension, with 60 participating countries around the world honoring entrepreneurial excellence.
A jury will elect the World Entrepreneur of the Year™ from the pool of national winners at the spring 2016 ceremony to be hosted in Monte Carlo.
Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.
Follow us on Twitter and www.insphero.com.
InSphero Granted Hanging Drop Patent in United States